[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,946,208
  • Shares Outstanding, K 40,085
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,610 K
  • EBIT $ -101 M
  • EBITDA $ -101 M
  • 60-Month Beta -1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 3
  • High Estimate $-0.67
  • Low Estimate $-0.84
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -46.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.00 +12.40%
on 06/02/26
151.99 -3.86%
on 06/18/26
+3.22 (+2.25%)
since 05/18/26
3-Month
130.00 +12.40%
on 06/02/26
183.67 -20.44%
on 04/09/26
-15.22 (-9.43%)
since 03/18/26
52-Week
56.10 +160.46%
on 07/02/25
200.00 -26.94%
on 02/03/26
+85.76 (+142.08%)
since 06/18/25

Most Recent Stories

More News
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 146.12 (-1.50%)
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 146.12 (-1.50%)
Belite Bio Q1 Earnings Call Highlights

Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations...

BLTE : 146.12 (-1.50%)
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected...

BLTE : 146.12 (-1.50%)
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 DRAGON...

BLTE : 146.12 (-1.50%)
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing...

BLTE : 146.12 (-1.50%)
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing...

BLTE : 146.12 (-1.50%)
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing...

BLTE : 146.12 (-1.50%)
Belite Bio to Participate in Four Upcoming Investor Conferences

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 146.12 (-1.50%)
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Belite expects to complete the new drug application submission in the second quarter of 2026 Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE...

BLTE : 146.12 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases....

See More

Key Turning Points

3rd Resistance Point 158.86
2nd Resistance Point 155.43
1st Resistance Point 150.77
Last Price 146.12
1st Support Level 142.68
2nd Support Level 139.25
3rd Support Level 134.59

See More

52-Week High 200.00
Last Price 146.12
Fibonacci 61.8% 145.03
Fibonacci 50% 128.05
Fibonacci 38.2% 111.07
52-Week Low 56.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.